News and Events
Combining bevacizumab with erlotinib shrinks tumors in patients with rare and aggressive kidney cancer
Seventy-two percent of patients with HLRCC-associated kidney cancers, for which there previously was no known drug treatment, responded to the therapy in a clinical trial.
Read MoreCelebrating CCR Careers: William G. Stetler-Stevenson, M.D., Ph.D.
For over three decades, William G. Stetler-Stevenson, M.D., Ph.D., has been a leader in the field of tissue inhibitors of metalloproteinases (TIMP) biology and extracellular matrix regulation of cancer.
Read MoreCelebrating CCR Careers: Allan M. Weissman, M.D.
Allan M. Weissman, M.D., who explored the essential underpinning of ubiquitin in cancer, announces his retirement from the NCI.
Read MoreCelebrating CCR Careers: Kathleen Kelly, Ph.D.
Kathleen Kelly, Ph.D., who pioneered new frameworks for modeling and exploring how prostate cancer cells respond to anti-cancer drugs, announces her retirement from the NCI.
Read MorePROTACtion against resistance of commonly used anti-cancer drug
Drugs known as PIM kinase inhibitors are used to treat a range of cancers, but many patients develop resistance to these medications. Recent research has led to a new class of therapeutics that target the mechanism of this resistance, resulting in increased death of cancer cells.
Read MoreCelebrating CCR Careers: Kenneth H. Kraemer, M.D.
For more than fifty years, Kenneth H. Kraemer, M.D., has investigated the molecular underpinnings and clinical manifestations of xeroderma pigmentosum, a rare disease that makes children highly vulnerable to skin damage and cancers from ultraviolet radiation, at the NCI.
Read MoreMolecular signature can identify tumor-targeting immune cells in the blood
Blood samples could be a new source of antitumor T cells for customized cancer immunotherapies.
Read MoreClinical trial researching olfactory neuroblastoma
A clinical trial led by Charalampos S. Floudas, M.D., D.M.Sc., M.S., Assistant Research Physician in the Center for Immuno-Oncology, is researching the symptoms and characteristics of olfactory neuroblastoma.
Read MoreNovel T cell stimulation technique drives potent anti-tumor response
Researchers combined an antibody with an immune-signaling molecule resulting in an agent called STAR0602. A version of the novel agent was designed for and tested in mice, which induced significant tumor shrinkage and increased survival across six different types of cancer while exhibiting little toxicity. The promising lab findings have prompted the launch of a clinical trial in people.
Read MoreExperimental vaccine halts respiratory growths from HPV infection
An experimental vaccine that trains a patient’s immune system to recognize HPV-infected cells could potentially be used to treat people with recurrent respiratory papillomatosis, according to results from an ongoing clinical trial.
Read MoreInactivating the WRN protein could kill colorectal and other cancer cells
Rapid inactivation of the Werner Syndrome helicase (WRN), a protein upon which cancer cells that exhibit microsatellite instability often rely for survival, could be effective in killing colorectal and other cancer cells and potentially guide the development of inhibitor drugs.
Read More